⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BlossomHill Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
BlossomHill Therapeutics
↗San Diego, USA
BlossomHill Therapeutics is a precision medicine oncology company focused on developing small-molecule therapies to address treatment resistance. Founded in 2020 by industry veterans Dr. J. Jean Cui and Y. Peter Li, the company aims to create 'medical masterpieces' by designing novel inhibitors that target specific cancer drivers while minimizing off-target toxicities.
The company's pipeline includes programs targeting EGFR-mutant non-small cell lung cancer (NSCLC) and hematologic malignancies. BlossomHill leverages a deep understanding of kinase inhibition and RNA splicing to develop therapies that overcome resistance mechanisms observed with existing standard-of-care treatments.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Private
Total Raised:$257M
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1/2
Modalities:Small molecule
Active Trials:2
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
J. Jean Cui - President and CEO
Y. Peter Li - Executive Chairman
Geoff Oxnard - EVP and Chief Medical Officer
Scientific Founders:J. Jean Cui, Y. Peter Li
LINKS
Website:bhtherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BlossomHill Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.